Dr Reddy’s Laboratories’ consolidated net profit increased 14 per cent at ₹1,437 crore in the second quarter ended September 30, 2025 compared to ₹1,255 crore in the corresponding quarter of the previous financial year.

The revenue of the Hyderabad-based company grew 9.8 percent to ₹8,805 crore in the quarter under review against ₹8,016 crore in the year ago period.

“Growth in Q2 was driven by momentum in branded markets and steady contributions from the Nicotine Replacement Therapy portfolio, which helped offset the decline in U.S. Lenalidomide sales. We remain focused on strengthening our core business, advancing key pipeline assets, driving productivity and Pursuing business development initiatives,’’ Co-Chairman & MD, G V Prasad said in a release on Friday. Comments

Published on Oct

See Full Page